The Refractory DermatoMyositis Index (ReDMI): a clinical tool to predict refractory disease in patients with dermatomyositis
Authors' conclusion
After external validation, the ReDMI may be a useful clinical tool to timely detect DM patients at risk of developing refractory disease who may be candidates to receive an early more aggressive therapy.
Study context
- Population
- Patients with dermatomyositis (DM) in a tertiary care centre in Mexico121 (72%) women
- Participants
- 168 patients
- Outcome
- Diagnosis of refractory disease: persistent disease activity 3 months after an adequate treatment course with GC and at least one immunosuppressant
Methodological detailssingle-centre, tertiary care centre, logistic regression, prediction index development with internal validation
- Single-centre
- Tertiary care centre
- Logistic regression
- Prediction index development with internal validation
Main finding
As reported in the abstract
Refractory disease
Odds ratio (95% CI)P value
Positivity for anti-TIF1-grefractoriness predictive factor
3.76(1.17–13.3)
P = 0.029Gastrointestinal disease activity (visual analogue scale)refractoriness predictive factor
1.11(1.004–1.249)
P = 0.04Alopeciarefractoriness predictive factor
2.5(1.11–5.7)
P = 0.026ReDMIoptimism corrected AUC 0.67, good internal validity and calibration
3.57(1.71–7.59)
- Patients who developed refractory disease
- 57 (33.9%)
Observational data: associations, not effects.
Further findings
Most frequent myositis-specific antibody
- Mi2
- 23.9%
Original publication
The Refractory DermatoMyositis Index (ReDMI): a clinical tool to predict refractory disease in patients with dermatomyositis. Clin Exp Rheumatol. Published 18 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →